Gentell, one of the world’s fastest-growing wound care companies, is proud to announce its acquisition of First Water Ramsbury in spring 2024.
In the coming years, we’ll be investing to strengthen the site’s status as the global leader in the development and manufacture of advanced wound dressings comprising specialist hydrogel polymers.
Product Categories
-
Exudate Management
-
Post-Op & Acute
-
Foot Care
-
First Aid & Burns
-
Emergency
-
NPWT Adhesives
-
Hydrogel Roll Stock
-
Co-developments
Featured Product:
FlexPore Hydroactive
The world’s most advanced sheet gel dressing.
Our capabilities
-
Product Design
We have a track record in strategic co-developments and IP generation. This allows us to offer strategic partners exclusive rights to novel products.
-
Materials Development
Across the Gentell R&D team, we can harness our growing team of polymer scientists in pursuit of improved materials.
-
Rapid Prototyping
We use our in-house prototyping capability means to provide partners with fast-track access to high fidelity dressings for internal evaluation.
-
Product Validation
Our technical services team provides the full suite of data generation services required to support regulatory submissions and powerful product claims.
-
Gel Manufacture
As part of Gentell, we’ll be taking gel manufacturing to the next level, through the development of improved processes and sustainable solutions fit for the century ahead.
-
Complex Conversion
Our in-house rotary conversion and in-line packing in the UK and Canada allows us to produce super-efficiently and in volume.
As a mark of Gentell’s commitment to pursuing innovation in wound care, Gentell Design Labs is being established at the First Water site. Our goal here is to build a centre of excellence for the development of unique, cost-effective and high performance wound care products.
The studios and labs will combine First Water’s expertise in wound dressings design with Gentell’s clinical knowledge, manufacturing infrastructure, scale, and access to an unparalleled amount of clinical data.
The result for our OEM partners? A level of collaboration experience that’s never been achieved before.